A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.

Many experts are frustrated and troubled by the state of HER2 testing, especially as new opportunities for tests are on the horizon. And as trials testing Herceptin at earlier stages and in ...

The first patients have been enrolled in the HEROES trial, exploring de-escalation of anti-HER2 therapy in metastatic HER2+ ...

It makes up about 70% of all breast cancer cases. HR+/HER2- breast cancer involves tumor cells that test positive for hormone ...

As genetic and biomarker tests become more common, so do new therapies that target specific tumor types and may lead to ...

In 2000, guidelines from the American Society of Clinical Oncology (ASCO) recommended that HER2 testing should be performed on all newly diagnosed breast cancer patients, [14] to assess whether ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

All patients with breast cancer who may be candidates for antibody-drug conjugate therapy should undergo HER2 testing to determine eligibility for Enhertu (fam-trastuzumab deruxtecan-nxki) — an agent ...

The availability of a simple immunohistochemical (IHC) test for HER2-low status is seen as critical to the successful rollout of Enhertu (trastuzumab deruxtecan) in this category of breast cancer ...

In February, AstraZeneca and Daiichi Sankyo teased the results of their pivotal trial of Enhertu in HER2-low breast cancer, and, at ASCO, they finally revealed the data – with the numbers every ...

a blood test can find the defect. The HER2 gene makes a protein called HER2 (human epidermal growth factor receptor 2). This protein is found on the surface of all breast cells and that helps them ...